2025
P1216 Mapping the Ulcerative Colitis patient journey in Saudi Arabia from healthcare professionals' perspective: A cross-sectional non-interventional study
Azzam N, Mosli M, Almutairdi A, Alghamdi M, Meeralam Y, Alolimi K, Arsalan M, Al-Bawardy B. P1216 Mapping the Ulcerative Colitis patient journey in Saudi Arabia from healthcare professionals' perspective: A cross-sectional non-interventional study. Journal Of Crohn's And Colitis 2025, 19: i2198-i2200. DOI: 10.1093/ecco-jcc/jjae190.1390.Peer-Reviewed Original ResearchComputer-assisted personal interviewsPatient journeyLack of awarenessTNF-a inhibitorsPatient-related barriersHealthcare professionals' perspectivesInstitutional review boardTreatment goalsBurden of ulcerative colitisFear of long-term side effectsSecond-line treatmentFirst-line treatmentQuality of lifeQuality of life improvementTNF-aHealthcare professionalsManagement of adultsSurvey domainsYears of experienceUlcerative colitisProfessional perspectivesOptimal careQuantitative interviewsImprove accessEndoscopic remissionEffectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis
Sannaa W, Almasry M, Peedikayil M, Grimshaw A, Attamimi M, AlMutairdi A, Al-Bawardy B. Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis. Therapeutic Advances In Gastroenterology 2025, 18: 17562848241312766. PMID: 39802627, PMCID: PMC11719443, DOI: 10.1177/17562848241312766.Peer-Reviewed Original ResearchOral vancomycin therapyPrimary sclerosing cholangitisIBD-PSCInflammatory bowel diseasePooled analysisClinical responseSclerosing cholangitisEpisodes of acute cholangitisFavorable side effect profilePooled analysis of studiesSystematic reviewInflammatory bowel disease associated with primary sclerosing cholangitisSide effect profileLong-term safetyClinical response/remissionVancomycin therapyOral vancomycinClinical remissionEndoscopic remissionAcute cholangitisMedian durationImmunosuppressive agentsNo episodesConcomitant treatmentEffect profile
2023
Oral Vancomycin Induced and Maintained Clinical and Endoscopic Remission in Ulcerative Colitis and Primary Sclerosing Cholangitis Post-liver Transplantation
Almomen H, Al-Bawardy B. Oral Vancomycin Induced and Maintained Clinical and Endoscopic Remission in Ulcerative Colitis and Primary Sclerosing Cholangitis Post-liver Transplantation. Inflammatory Bowel Diseases 2023, 29: 837-838. PMID: 36888548, DOI: 10.1093/ibd/izad040.Peer-Reviewed Original Research
2022
Effect of obesity on vedolizumab response in inflammatory bowel disease
Levine LJ, Gaidos JKJ, Proctor DD, Viana AV, Al-Bawardy B. Effect of obesity on vedolizumab response in inflammatory bowel disease. Annals Of Gastroenterology 2022, 35: 275-280. PMID: 35599926, PMCID: PMC9062841, DOI: 10.20524/aog.2022.0699.Peer-Reviewed Original ResearchBody mass indexInflammatory bowel diseaseSteroid-free clinical remissionNon-obese groupC-reactive proteinObese groupCRP normalizationEndoscopic remissionIBD patientsBowel diseaseDose escalationNormal serum C-reactive proteinMedian body mass indexSerum C-reactive proteinHigher body mass indexEndoscopic remission ratesEffect of obesityVedolizumab discontinuationVedolizumab levelsClinical remissionMedian followRemission rateSecondary outcomesMedian agePrimary outcome
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply